论文信息 - Kinetics of intravenous pyridostigmine in man.

Kinetics of intravenous pyridostigmine in man.

ing agent, practolol. J. Pharmac. exp. Ther., 175, 338-347. SMITH, L.H. (1980). The chemistry of beta-adrenergic blocking agents relative to cardioselectivity. Royal Society of Medicine, International Congress & Symposium Series No. 19. pp. 93-96. VERMEIJ, P., EL SHERBINI-SCHEPERS, M. & VAN ZWIETEN, P.A. (1978). The disposition of timolol in man. J. Pharm. Pharmac., 30, 53-55. WOODS, P. & ROBINSON, M.L. (1981). An investigation of the comparative liposolubilities of 8-adrenergic blocking agents. J. Pharm. Pharmac. in press.

A. Dehghan | T. N. Calvey | N. Williams | K. Chan

[1] W. Murray,et al. Cimetidine and the amylase/creatinine clearance ratio. , 1980, British journal of clinical pharmacology.

[2] K. Wormsley,et al. INHIBITION OF PENTAGASTRIN-STIMULATED AND NOCTURNAL GASTRIC SECRETION BY RANITIDINE A New H2-receptor Antagonist , 1979, The Lancet.

[3] M. Wareing,et al. Pharmacokinetics and pharmacological effects of neostigmine in man. , 1979, British journal of clinical pharmacology.

[4] C. Macnee,et al. PLASMA CLEARANCE OF NEOSTIGMINE AND PYRIDOSTIGMINE IN THE DOG , 1978, British journal of pharmacology.

[5] J. Baty,et al. A quantitative gas-liquid chromatographic method for the determination of neostigmine and pyridostigmine in human plasma. , 1976, Journal of chromatography.

[6] E. Eger,et al. Comparative Times to Peak Effect and Durations of Action of Neostigmine and Pyridostigmine , 1974, Anesthesiology.

[7] S. Somani,et al. Pyridostigmine metabolism in man , 1972, Clinical pharmacology and therapeutics.

[8] R. Katz. Pyridostigmin (mestinon) as an antagonist of d-tubocurarine. , 1967, Anesthesiology.